Travis J. Cook

TL;DR: It is discovered that CSF α-synuclein was readily transported to blood, with a small portion being contained in exosomes that are relatively specific to the central nervous system (CNS), which may lead to a more convenient and robust assessment of Parkinson’s disease clinically.

TL;DR: Alzheimer's disease and Parkinson's disease involve tau pathology, where Tau is detectable in blood, but its clearance from neuronal cells and the brain is poorly understood.

TL;DR: Blood levels of patients with Parkinson disease at various stages, Alzheimer disease, and healthy controls are measured to identify potential peripheral biomarkers of PD, suggesting that post-translationally modified isoforms of DJ-1 from whole blood are candidate biomarker of late-stage Parkinson disease.

TL;DR: This review summarizes major advances in biomarker discovery for diagnosis, differential diagnosis and progression of Parkinson's disease, with emphasis on neuroimaging and biochemical markers.

TL;DR: It is suggested that astrocytic mitochondrial Dlp1 is a key protein in mitochondrial dynamics and decreased DLP1 may interfere with neuron survival in PD by disrupting Ca(2+)-coupled glutamate uptake.